Next Gen Blood Screening
Device
Abbott Laboratories
Total Payments
$276,900
Transactions
3
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $275,000 | 1 | 0 |
| 2018 | $1,900 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $276,900 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Novel Viruses Associated with Human Diseases | Abbott Laboratories | $275,000 | 0 |
| HIV HTLV and Hepatitis Specimen Collection | Abbott Laboratories | $1,900 | 0 |
Top Doctors Receiving Payments for Next Gen Blood Screening
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $276,900 | 3 |
Ad
Manufacturing Companies
- Abbott Laboratories $276,900
Product Information
- Type Device
- Total Payments $276,900
- Total Doctors 0
- Transactions 3
About Next Gen Blood Screening
Next Gen Blood Screening is a device associated with $276,900 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2018 to 2019. In 2019, $275,000 was paid across 1 transactions to 0 doctors.
The most common payment nature for Next Gen Blood Screening is "Unspecified" ($276,900, 100.0% of total).
Next Gen Blood Screening is associated with 2 research studies, including "Novel Viruses Associated with Human Diseases" ($275,000).